AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01851109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: genetic counseling
Description: The genetic counseling sessions are conducted by a licensed genetic counselor, certified by the American Board of Genetic Counseling and the American Board of Medical Genetics. This clinical counseling session may include, but is not limited to the following:~1. A review of medical and family history information to determine which genetic test (BRCA, HNPCC, p53, etc.), if any, is appropriate;~2. Discuss how the results - positive or negative - affect cancer risk~3. Discuss how cancer risk might be managed (surveillance, prophylactic surgery, oral contraceptives, etc.);~4. Discuss how the test is conducted and what the results might be (positive, negative, uncertain);~5. Discuss the disadvantages of genetic testing (cost, insurance coverage, worry about insurance discrimination, uncertain results, etc.) and the psychological and emotional issues surrounding testing, etc.
Study NCT04872062 — intervention group
Intervention type: DEVICE
Intervention: NIV cards
Description: Reading the data available on the NIV cards
Study NCT04872062 — intervention group
Intervention type: OTHER
Intervention: Medical file
Description: Using the data available in the medical file including clinical data, blood gas results, nocturnal oximetry results
Study NCT02338609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: At the discretion of the investigator, pediatric patients could be treated with commercially available everolimus, as per local product information / standard of care. Treatment duration and dose modifications were at the investigator's discretion, as per the local product information.
Study NCT04037397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti Arrhythmics
Description: Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
Study NCT00398333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid enriched nutritional supplement
Description: Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
Study NCT03711227 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin lab test
Description: A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
Study NCT04285502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SURGICAL DRAIN
Description: A surgical drain is a tube used to remove blood, abscess and any type of fluid at the site of the place it is inserted
Study NCT02635659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encapsulated nutrients
Study NCT02635659 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04037397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation
Description: Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins
Study NCT01799954 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DNA-HIV-PT123
Description: 4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)
Study NCT01799954 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: NYVAC-HIV-PT1
Description: (along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
Study NCT06688357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedX 1116 Rehab Console
Description: This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
Study NCT06688357 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MedX 1116 Rehab Console
Description: This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
Study NCT01799954 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: NYVAC-HIV-PT4
Description: (along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
Study NCT04351776 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VR-Biofeedback
Description: Participants will be instructed to use the Mindful Aurora application
Study NCT04351776 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VR-Distraction
Description: Participants will be instructed to use one of three applications
Study NCT04351776 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 360 Video
Description: Participants will be instructed which video to view
Study NCT03799172 — intervention group
Intervention type: DRUG
Intervention: Echinocandin treatment
Description: Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
Study NCT03799172 — intervention group
Intervention type: DRUG
Intervention: Triazole treatment
Description: Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida.
Study NCT01863550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC or IV
Study NCT01863550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT00736151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ralfinamide
Description: Oral tablets administered at rising doses of 80 - 320 mg/day
Study NCT00736151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ralfinamide
Description: Oral tablets administered at rising doses of 80 - 320 mg/day
Study NCT02292355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
Study NCT02868879 — intervention group
Intervention type: OTHER
Intervention: Quantitative multiparametric and functional MRI
Description: Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2\*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks.
Study NCT01863550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02776735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form:Solution Route of administration: Subcutaneous
Study NCT01863550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01044433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally
Study NCT01044433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT01799954 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AIDSVAX® B/E
Description: 300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
Study NCT01468688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571
Study NCT05051345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information on the services provided for pregnant women and smoking cessation
Study NCT05051345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive tobacco cessation self-help materials
Study NCT05051345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive Smoke-Free Homes mailings
Study NCT05051345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Download and use the Wellness app
Study NCT05051345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05051345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive Smoke-Free Homes kit
Study NCT05051345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05051345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone counseling sessions
Study NCT05051345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive a coaching call from a Baby Steps for Health counselor
Study NCT05051345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive telephone counseling sessions
Study NCT03753074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Tenofovir Alafenamide 25mg, Tablet, Oral, Daily
Study NCT01863550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01799954 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo for DNA/NYVAC
Description: Sodium Chloride for injection, 0.9% administered IM
Study NCT01799954 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo for AIDSVAX(R) B/E
Description: 600 mcg of aluminum hydroxide adjuvant, administered IM
Study NCT03722303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat Injection
Description: Used by plastic surgeons, lipografting injects autologous fat to correct contour deformities. Plastic surgeons have witnessed the regenerative properties of fat transfer, and these clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions. This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors stimulate nerve regeneration.
Study NCT03722303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Injection
Description: Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
Study NCT01468688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 combination therapy
Study NCT03993080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality relaxation
Description: 1-3.5 minute 360° videos
Study NCT02500615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG liquid vehicles
Description: The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
Study NCT01546363 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: phlebotomy
Study NCT05228717 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care Ultrasound
Description: q48-72h point of care ultrasound of the lungs, heart, and IVC (inferior vena cava)
Study NCT04224662 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study NCT00841620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haemorrhoidectomy a.m. Milligan
Description: Surgery
Study NCT00841620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled anopexy
Description: Surgery
Study NCT01863550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03039972 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT04528173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac (0.5mg/kg; maximum 15mg intravenously) will be given at end of procedure after evaluation for hemostasis.
Study NCT04528173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (1ug/kg with maximum 50ug intravenously) will be given at beginning of procedure.
Study NCT04528173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine (0.05-0.1 mg/kg intravenously) will be given intra-operatively per institutional standard clinical care.
Study NCT04528173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl (0.5-2 ug/kg intravenously) will be given intra-operatively per institutional standard clinical care.
Study NCT02812407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal Impedance
Description: During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.~* The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second~* At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds~* And at 20 cm
Study NCT00739453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: administered orally
Study NCT00739453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: administered orally
Study NCT03258177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Visit
Description: Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
Study NCT03194503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VL Coaching training using C-MAC video laryngoscope
Description: Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card).
Study NCT03491943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-assisted midline approach
Description: A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via midline approach.
Study NCT03491943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-assisted paramedian approach
Description: A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
Study NCT00457366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD
Study NCT00457366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary
Study NCT00457366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.
Study NCT00457366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cogentin
Description: given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
Study NCT00844818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Quitline Enrollment
Description: The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
Study NCT02894632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI compatible motion sensor (MARMOT)
Description: MRI with motion control (several motion sensors placed on the volunteer's body)
Study NCT04163146 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurements of PEF and FEV1
Description: Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone
Study NCT03360981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incretins
Description: after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
Study NCT03163511 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-02 Combination Product
Description: PEC-01 cells loaded into a Delivery Device
Study NCT04516044 — intervention group
Intervention type: BEHAVIORAL
Intervention: Video games
Description: See arm description
Study NCT00337350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Rosiglitazone 4mg, one capsule per day for eight weeks
Study NCT00337350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo for rosiglitazone 4mg/day
Study NCT02852772 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive function tests
Study NCT01967758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 1
Description: Four doses of IV ADU-623 at a dose of 3 x 10\^7cfu
Study NCT01967758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 2
Description: Four doses of IV ADU-623 at a dose of 3 x 10\^8cfu
Study NCT03360981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Incretins
Description: after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
Study NCT01967758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 3
Description: Four doses of IV ADU-623 at a dose of 3 x 10\^9cfu
Study NCT01967758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
Study NCT03885206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Level of healthcare services
Description: Patiens judged to be eligible for admittance to a municipal acute care wrad will be admitted to hospital as an intervnetion, to be able to compare same patient groups.
Study NCT06120361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma APS 2 score
Description: APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study NCT05274139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-MTX-Ara-C regimen
Description: HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Study NCT05274139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTD regimen
Description: FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Study NCT06120361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma p-tau217/np-tau217
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study NCT06120361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma p-tau217
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.